WO2005053669A8 - Use of omega-3 polyunsaturated fatty acids for sleep apnoea - Google Patents

Use of omega-3 polyunsaturated fatty acids for sleep apnoea

Info

Publication number
WO2005053669A8
WO2005053669A8 PCT/FR2004/003063 FR2004003063W WO2005053669A8 WO 2005053669 A8 WO2005053669 A8 WO 2005053669A8 FR 2004003063 W FR2004003063 W FR 2004003063W WO 2005053669 A8 WO2005053669 A8 WO 2005053669A8
Authority
WO
WIPO (PCT)
Prior art keywords
omega
fatty acids
polyunsaturated fatty
sleep apnoea
sleep
Prior art date
Application number
PCT/FR2004/003063
Other languages
French (fr)
Other versions
WO2005053669A1 (en
Inventor
Pierre Fabre
Christophe Przybylski
Jean Gardette
De Andrade Lemes Lucas Neves
Eliete Bouskela
Original Assignee
Pf Medicament
Pierre Fabre
Christophe Przybylski
Jean Gardette
De Andrade Lemes Lucas Neves
Eliete Bouskela
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament, Pierre Fabre, Christophe Przybylski, Jean Gardette, De Andrade Lemes Lucas Neves, Eliete Bouskela filed Critical Pf Medicament
Publication of WO2005053669A1 publication Critical patent/WO2005053669A1/en
Publication of WO2005053669A8 publication Critical patent/WO2005053669A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to the use of Omega-3 polyunsaturated fatty acids for the preparation of a medicament that is intended for the treatment of sleep apnoea syndrome. The Omega-3 polyunsaturated fatty acids are preferably selected from the group comprising EPA, DHA and mixtures of same.
PCT/FR2004/003063 2003-12-01 2004-11-30 Use of omega-3 polyunsaturated fatty acids for sleep apnoea WO2005053669A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0314080A FR2862873A1 (en) 2003-12-01 2003-12-01 USE OF POLYUNSATURATED FATTY ACIDS OMEGA 3 IN THE APNEA OF SLEEP
FR0314080 2003-12-01

Publications (2)

Publication Number Publication Date
WO2005053669A1 WO2005053669A1 (en) 2005-06-16
WO2005053669A8 true WO2005053669A8 (en) 2005-09-09

Family

ID=34566276

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2004/003063 WO2005053669A1 (en) 2003-12-01 2004-11-30 Use of omega-3 polyunsaturated fatty acids for sleep apnoea

Country Status (2)

Country Link
FR (1) FR2862873A1 (en)
WO (1) WO2005053669A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503164A (en) * 2007-11-12 2011-01-27 サムサラ・メディシン・アクチエボラーグ Methods related to breathing disorders
JP2014505729A (en) * 2011-02-16 2014-03-06 ピヴォタル セラピューティクス インコーポレイテッド Cholesterol absorption inhibitors (azetidinone) and omega-3 fatty acids (EPA, DHA, DPA) for the reduction of cholesterol and cardiovascular events
US9119826B2 (en) * 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
EP2675446A1 (en) * 2011-02-16 2013-12-25 Pivotal Therapeutics, Inc. Omega 3 formulations comprising epa, dha and dpa for treatment of risk factors for cardiovascular disease
US8951514B2 (en) * 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US20120302639A1 (en) * 2011-02-16 2012-11-29 Pivotal Therapeutics Inc. Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
JP2014505732A (en) * 2011-02-16 2014-03-06 ピヴォタル セラピューティクス インコーポレイテッド Statins and omega-3 fatty acids (EPA, DHA and DPA) for use in cardiovascular disease
CA2827561A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Omega 3 fatty acid diagniostic assay for the dietary management of patients with cardiovascular disease (cvd)
US8952000B2 (en) * 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
DE60234246D1 (en) * 2001-04-06 2009-12-17 Univ Illinois CANNABINOIDS FOR TREATING BLEEDING DURING SLEEPING

Also Published As

Publication number Publication date
FR2862873A1 (en) 2005-06-03
WO2005053669A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
WO2008036353A3 (en) Omega-3 diglyceride emulsions
HUP0303817A3 (en) Medium-chain length fatty acids, glycerides and analogues as neutrophile survival and activation factors and pharmaceutical compositions containing them
AU2003210210A1 (en) The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure
WO2004112776A3 (en) Inflammatory disease treatment
IL210233A (en) Omega-3 fatty acid formulations containing epa and dha and no active ingredients other than omega-3 fatty acids
AU2003253816A1 (en) Epa and dha enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
PT1310249E (en) UTILIZATION OF POLY-INSATURATED FATTY ACIDS FOR PRIMARY PREVENTION OF SERIOUS CARDIOVASCULAR EVENTS
WO2004078166A3 (en) Use of omega-3-fatty acids in the treatment of diabetic patients
WO2006017627A3 (en) Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance
WO2008018043A3 (en) Methods of improving bone health and muscle health
CA2458067A1 (en) Use of flibanserin in the treatment of sexual disorders
WO2008028631A3 (en) Skin care composition
AU2003217759A1 (en) Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression
WO2008006607A3 (en) Pharmaceutical and nutraceutical products comprising vitamin k2
WO2007070611A3 (en) Nutritional supplement containing long-chain polyunsaturated fatty acids
WO2009091538A8 (en) Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia
EP2510927A3 (en) Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage
EP1698685A4 (en) Fat composition
WO2006017692A3 (en) Novel fenofibrate formulations and related methods of treatment
EP2444082A3 (en) Hydroxymethylbutyrate compositions and uses thereof
MXPA02012689A (en) Therapeutic combinations of fatty acids.
WO2005053669A8 (en) Use of omega-3 polyunsaturated fatty acids for sleep apnoea
UA88030C2 (en) Composition containing omega-3 fatty acids and omega-6 fatty acids for use in the treatment of dry eye syndrome
WO1999066914A3 (en) Neuroprotective composition for the prevention and/or treatment of nervous and behavioural alterations due to anxiety states or depression, comprising acetyl-l-carnitine and hypericin
AU2614200A (en) Composition for stabilizing and potentiating the action of anti-angiogenic substances by polyunsaturated fatty acids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 24/2005 ADD "DECLARATION UNDER RULE 4.17: - OF INVENTORSHIP (RULE 4.17(IV)) FOR US ONLY."

NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase